Alnylam Pharmaceuticals
ALNY
#641
Rank
C$45.68 B
Marketcap
$352.90
Share price
-1.30%
Change (1 day)
73.55%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -C$0.34 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$2.24 Billion. , an increase over its 2023 earnings that were of -C$0.46 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -C$0.35 Billion-24.59%
2023 -C$0.46 Billion-67.84%
2022 -C$1.41 Billion36.93%
2021 -C$1.03 Billion-8.04%
2020 -C$1.12 Billion-15.66%
2019 -C$1.33 Billion12.23%
2018 -C$1.19 Billion62.91%
2017 -C$0.73 Billion17.78%
2016 -C$0.62 Billion43.44%
2015 -C$0.43 Billion60.69%
2014 -C$0.27 Billion98.2%
2013 -C$0.14 Billion
2011 -C$79.44 Million27.48%
2010 -C$62.32 Million-10.92%
2009 -C$69.96 Million95.77%
2008 -C$35.74 Million
2006 -C$57.25 Million-9.13%
2005 -C$63 Million34.74%
2004 -C$46.76 Million36.79%
2003 -C$34.18 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$0.87 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.92 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.18 B-154.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.18 Billion-49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$59.95 Million-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
C$19.76 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$11.50 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-C$0.41 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel